All In Biotech

Drug Trial Radar · NCT05651711

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 726 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

726

Actual

Start

Dec 14, 2022

Primary completion

Jun 5, 2024

Study completion Aug 27, 2024

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Dec 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The co-primary objectives of the study are to: * Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD). * Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema Area and Severity Index (EASI).

Conditions

  • Atopic Dermatitis

Interventions

  • RocatinlimabDrug

    Rocatinlimab will be administered through a subcutaneous (SC) injection.

  • PlaceboOther

    The matching placebo will be administered through a SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Achieved Validated Investigator's Global Assessment for AD (vIGA-AD) 1 Response With Presence of Only Barely Perceptible Erythema or vIGA-AD 0 Response (Revised Investigator's Global Assessment [rIGA] 0/1) at Week 24Time frame: Baseline and Week 24
  2. Number of Participants Who Achieved ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 24Time frame: Baseline and Week 24

Locations

197 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Solutions of Arizona, PC

    Litchfield Park, Arizona

  • Center for Dermatology and Plastic Surgery

    Scottsdale, Arizona

  • Clinical Trials Institute of Northwest Arkansas

    Fayetteville, Arkansas

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • Velocity Clinical Research Chula Vista

    Chula Vista, California

  • West Coast Research LLC

    Dublin, California

  • California Dermatology and Clinical Research Institute

    Encinitas, California

  • Center for Dermatology Clinical Research Inc

    Fremont, California

  • Velocity Clinical Research - San Diego

    La Mesa, California

  • Velocity Clinical Research - North Hollywood

    North Hollywood, California

  • Cura Clinical Research

    Palmdale, California

  • University of California at San Francisco, Dermatology Clinic at Mount Zion

    San Francisco, California

  • Clinical Science Institute

    Santa Monica, California

  • Clarity Dermatology

    Castle Rock, Colorado

  • Velocity Clinical Research - Denver

    Denver, Colorado

  • Foxhall Research Center

    Washington D.C., District of Columbia

  • Renaissance Research and Medical Group

    Cape Coral, Florida

  • Driven Research LLC

    Coral Gables, Florida

  • Saint Jude Clinical Research

    Doral, Florida

  • Direct Helpers Research Center

    Hialeah, Florida

  • Glick Skin Institute

    Margate, Florida

  • Miami Dade Medical Research Institute, LLC

    Miami, Florida

  • Innovation Medical Research Center Inc

    Palmetto Bay, Florida

  • University of South Florida Health Morsani Center for Advanced Healthcare

    Tampa, Florida

  • Advanced Medical Research PC

    Sandy Springs, Georgia

  • Sneeze, Wheeze, and Itch Associates, LLC

    Normal, Illinois

  • The South Bend Clinic LLP

    South Bend, Indiana

  • Options Research Group LLC

    West Lafayette, Indiana

  • Dermatology and Skin Cancer Center of Overland Park

    Overland Park, Kansas

  • DS Research

    Louisville, Kentucky

  • Kentucky Advanced Medical Research LLC

    Murray, Kentucky

  • MetroBoston Clinical Partners

    Brighton, Massachusetts

  • Wendy Sadoff MD Dermatology PC

    Farmington Hills, Michigan

  • Revival Research Institute LLC

    Troy, Michigan

  • Somerset Skin Centre

    Troy, Michigan

  • Advanced Dermatology of the Midlands

    Omaha, Nebraska

  • James Del Rosso Dermatology Research

    Las Vegas, Nevada

  • Skin Cancer and Dermatology Institute

    Reno, Nevada

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Weiss Medical

    Riverdale, New Jersey

Showing 40 of 197 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.